

Please type a plus sign inside this box → ☐



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number 09/884,384

Filing Date June 19, 2001

First Named Inventor Huda Y. Zoghbi

Group Art Unit 1632

Examiner Name Not Yet Assigned

Attorney Docket Number HO-P01492US2

RECEIVED

SEP 19 2002

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)

☐ Fee Transmittal Form

☐ Fee Attached

☐ Amendment/Reply

☐ After Final

☐ Affidavits/declaration(s)

☐ Extension of Time Request

☐ Express Abandonment Request

☒ Information Disclosure Statement

☐ Certified Copy of Priority Document(s)

☐ Response to Missing Parts/Incomplete Application

☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

☐ Assignment Papers (for an Application)

☐ Drawing(s)

☐ Licensing-related Papers

☐ Petition

☐ Petition to Convert to a Provisional Application

☐ Power of Attorney, Revocation Change of Correspondence Address

☐ Terminal Disclaimer

☐ Request for Refund

☐ CD, Number of CD(s) _____

☐ After Allowance Communication to Group

☐ Appeal Communication to Board of Appeals and Interferences

☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☐ Other Enclosure(s) (please identify below)

Remarks

Applicants believe no fees are due. However, if fees are due, please charge them to the account 06-2375 of Fulbright & Jaworski L.L.P. under Order No. P01492US2, from which the undersigned is authorized to withdraw.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual Name

FULBRIGHT & JAWORSKI L.L.P.
Melissa L. Sistrunk, Reg. No. 45,579

Signature

Melissa Sistrunk

Date

Sept. 17, 2002

Transmittal

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU186313425US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: 9/17/02 Signature: Monica L. Thomas (Monica Thomas)

SEP 19 2002

TECH CENTER 1600/2900


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU1867134254 in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated:

Signature:

Monica Thomas
(Monica Thomas)

Docket No.: HO-P01492US2
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Huda Y. Zoghbi, et al.

Application No.: 09/884,384

Group Art Unit: 1632

Filed: June 19, 2001

Examiner: Not Yet Assigned

For: CHAPERONE SUPPRESSION OF ATAXIN-
1 AGGREGATION AND ALTERED
SUBCELLULAR PROTEASOME
LOCALIZATION IMPLY PROTEIN
MISFOLDING IN SCA1

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned.

Applicants submit two Form PTO-1449, the references of which are not supplied because they were previously cited by or submitted to the Office in prior U.S. Patent Application No. 09/321,916, filed May 28, 1999 and relied upon in this application for an earlier filing date under 35 U.S.C. 120. The original IDS was filed December 6, 1999, and a supplemental IDS was filed July 19, 2000. If re-submission of the references is required, please let the undersigned know for quick resolution.



While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. HO-P01492US2. A duplicate copy of this paper is enclosed.

Dated: *Sept. 17, 2002*

Respectfully submitted,

By *Melissa L. Sistrunk*

Melissa L. Sistrunk

Registration No.: 45,579

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-3735

(713) 651-5246 (Fax)

Agent for Applicant

SEP 17 2002

Sheet 1 of 4

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket No. (Optional)
P01492US1

RECEIVED

Application Number
09/321,916Applicant:
Zoghbi, et al.

SEP 19 2002

Filing Date:
05/28/99Group Art Unit
1633

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENT(S)

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1.	Barkats, M. et al.; Adenovirus in the Brain: Recent Advances of Gene Therapy for Neurodegenerative Diseases; <i>Prog. In Neurobiol.</i> 55:333-341 (1998).
2.	Barkats, M. et al.; Intrastriatal Grafts of Embryonic Mesencephalic Rat Neurons Genetically Modified Using an Adenovirus Encoding Human Cu/Zn Superoxide Dismutase; <i>Neuroscience</i> 78:703-713 (1997).
3.	Beissinger, Martina and Buchner, Johannes; How Chaperones Fold Proteins; <i>Biol. Chem.</i> 379:245-259 (1998).
4.	Bilang-Bleuel, A. et al.; Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease; <i>Proc. Natl. Acad. Sci. USA</i> 94: 8818-8823 (1997).
5.	Blömer, U. et al.; Applications of gene therapy to the CNS; <i>Hum. Mol. Genet.</i> 5:1397-1404 (1996).
6.	Bruening, W. et al.; Up-Regulation of Protein Chaperones Preserves Viability of Cells Expressing Toxic Cu/Zn Superoxide Dismutase Mutants Associated with Amyotrophic Lateral Sclerosis; <i>J. Neurochem.</i> 72:693-699 (1999).
7.	Bukau, Bernd and Horwich, Arthur L.; The Hsp70 and Hsp60 Chaperone Machines; <i>Cell</i> 92:351-366 (1998).
8.	Caughey, B. et al.; Congo Red Inhibition of Scrapie Agent Replication; <i>J. Virol.</i> 67:6270-6272 (1993).
9.	Caughey, Byron and Race, Richard E.; Potent Inhibition of Scrapie-Associated PrP Accumulation by Congo Red; <i>J. Neurochem.</i> 59:768-771 (1992).
10.	Caughey, Byron and Raymond, Gregory J.; Sulfated Polyanion Inhibition of Scrapie-Associated PrP Accumulation in Cultured Cells; <i>J. of Virol.</i> 67:643-650 (1993).
11.	Cha, J-H. J.; et al.; Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease; <i>Phil. Trans. R. Soc. Lond.</i> 354:981-989 (1999).
12.	Chai, Y. et al.; Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation <i>in vitro</i> ; <i>Hum. Mol. Gen.</i> 8:673-682 (1999).
13.	Choi-Lundberg, D. L. et al.; Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy; <i>Science</i> 275:838-841 (1997).
14.	Csermely, P. et al.; The 90-kDa Molecular Chaperone Family: Structure, Function, and Clinical Applications. A Comprehensive Review; <i>Pharmacol. Ther.</i> 79:129-168 (1998).
15.	Cummings, C. J. et al.; Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1; <i>Nature Genet.</i> 19:148-154 (1998).
16.	Cummings, Christopher J. and Huda Y. Zoghbi; Fourteen and counting: unraveling trinucleotide repeat diseases; <i>Hum. Mol. Gen.</i> 9:909-916 (2000).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Sheet 2 of 4



RECEIVED

SEP 19 2002

PTO-1449

Docket No. (Optional)
P01492US1Application Number
09/321,916INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant:
Zoghbi, et al.Filing Date:
05/28/99Group Art Unit
1633

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENT(S)

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

17.	Cummings, C. J. et al.; Mutation of the E6-AP Ubiquitin Ligase Reduces Nuclear Inclusion Frequency While Accelerating Polyglutamine-Induced Pathology in <i>SCA1</i> Mice; <i>Neuron</i> X:879-892 (1999).
18.	Déglon, N.; Central Nervous System Delivery of Recombinant Ciliary Neurotrophic Factor by Polymer Encapsulated Differentiated C.C.; Myoblasts; <i>Hum. Gene Ther.</i> 7:2135-2146 (1996).
19.	Doran S. E. et al.; Gene Expression from Recombinant Viral Vectors in the Central Nervous System after Blood-Brain Barrier Disruption; <i>Neurosurgery</i> 36:965-970 (1995).
20.	Emerich, D. F. et al.; Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease; <i>Nature</i> 386:395-399 (1997).
21.	Floyd, Jennifer A. and Hamilton, Bruce A.; Intracellular Inclusions and the Ubiquitin-Proteasome Pathway: Digestion of a Red Herring?; <i>Neuron</i> 24(4):765-766 (1999).
22.	Giménez y Ribotta, M. et al.; Prevention of Motoneuron Death by Adenovirus-Mediated Neurotrophic Factors; <i>J. Neurosci. Res.</i> 48:281-285 (1997).
23.	Graham, Frank L. and Prevec, Ludvik; Chapter 11- Manipulation of Adenovirus Vectors; <i>Methods in Molecular Biology, Vol 7: Gene Transfer and Expression Protocols</i> ; E. J. Murray, Ed.; The Humana Press Inc.; p. 109-128 (1991).
24.	Haase, G. et al.; Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors; <i>Nature Medicine</i> 3:429-436 (1997).
25.	Hedera, P. et al.; Spastic paraplegia, ataxia, mental retardation (SPAR): a novel genetic disorder; (abstract).
26.	Hendrick, Joseph P. and Hartl, Franz-Ulrich; Molecular Chaperone Functions of Heat-Shock Proteins; <i>Annu. Rev. Biochem.</i> 62:349-384 (1993).
27.	Horellou, P. et al.; Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease; <i>NeuroReport</i> 6:49-53 (1994).
28.	Kaytor, Michael D. and Warren, Stephen T.; Aberrant Protein Deposition and Neurological Disease; <i>J. Biol. Chem.</i> 274:37507-37510 (1999).
29.	Kazemi-Esfarjani, Parsa and Benzer, Seymour; Genetic Suppression of Polyglutamine Toxicity in <i>Drosophila</i> ; <i>Science</i> 287:1837-1840 (2000).
30.	Kobayashi, Y. et al.; Chaperones Hsp70 and Hsp40 Suppress Aggregate Formation and Apoptosis in Cultured Neuronal Cells Expressing Truncated Androgen Receptor Protein with Expanded Polyglutamine Tract; <i>J. Biol. Chem.</i> 275:8772-8778 (2000).
31.	Kojima, H. et al.; Construction and Characterization of Adenoviral Vector Expressing Biologically Active Brain-Derived Neurotrophic Factor; <i>Biochem. Biophys. Res. Commun.</i> 212:712-717 (1995).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



RECEIVED

SEP 19 2002

TO-1449										Docket No. (Optional) TECH CENTER 1600/2900 P01492US1										Application Number 09/321,916																																							
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)																														Applicant: Zoghbi, et al.										Filing Date: 05/28/99										Group Art Unit 1633									
U.S. PATENT DOCUMENTS																																																											
EXAMINER INITIAL					DOCUMENT NUMBER										DATE					NAME										CLASS					SUBCLASS					FILING DATE IF APPROPRIATE																			
FOREIGN PATENT DOCUMENT(S)																																																											
					DOCUMENT NUMBER										DATE					COUNTRY										CLASS					SUBCLASS					TRANSLATION YES NO																			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																																																											
					32.					Koshy, Benna T. and Zoghbi Huda Y.; The CAG/Polyglutamine Tract Diseases: Gene Products and Molecular Pathogenesis; <i>Brain Pathol.</i> 7:927-942 (1997).																																																	
					33.					Krobitsch, Sylvia and Lindquist, Susan; Aggregation of huntington in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins; <i>Proc. Natl. Acad. Sci. USA</i> 97:1589-1594.																																																	
					34.					Le Gal La Salle, G. et al.; An Adenovirus Vector for Gene Transfer into Neurons and Glia in the Brain; <i>Science</i> 259:988-990 (1993).																																																	
					35.					Lin, X et al.; Expanding Our Understanding of Polyglutamine Diseases through Mouse Models; <i>Neuron</i> 24:499-502 (1999).																																																	
					36.					Lowe, J. et al.; Ubiquitin is a Common Factor in Intermediate Filament Inclusion Bodies of Diverse Type in Man, Including those of Parkinson's Disease, Pick's Disease, and Alzheimer's Disease, as well as Rosenthal Fibres in Cerebellar Astrocytomas, Cytoplasmic Bodies in Muscle, and Mallory Bodies in Alcoholic Liver Disease; <i>J. of Pathol.</i> 155:9-15 (1988).																																																	
					37.					MacDonald, Marcy E.; gadzooks!; <i>Nature Genetics</i> 23:10-11 (1999).																																																	
					38.					Marber, M. S. et al.; Overexpression of the Rat Inducible 70-kD Heat Stress Protein in a Transgenic Mouse Increases the Resistance of the Heart to Ischemic Injury; <i>J. Clin. Invest.</i> 95:1446-1456 (1995).																																																	
					39.					Mayer, Matthias P. and Bukau, Bernd; Hsp70 Chaperone Systems: Diversity of Cellular Functions and Mechanism of Action; <i>Biol. Chem.</i> 379:261-268 (1998).																																																	
					40.					Mayer, R. J.; The ubiquitin/26S proteasome system and neurological disease - a personal view. (opinion).																																																	
					41.					Neuwelt; Edward A.; Cellular and Molecular Neurosurgery II - Comments; <i>Neurosurgery</i> 40:812-813 (1997).																																																	
					42.					Orr, Harry T. and Zoghbi, Huda Y.; Reversing Neurodegeneration: A Promise Unfolds; <i>Cell</i> 101:1-4 (2000).																																																	
					43.					Price, D. L. et al.; Neurodegenerative Diseases and Model Systems; <i>Neurodegenerative Diseases</i> ; LXI:725-738 (1996).																																																	
					44.					Priola, S. A. et al.; Porphyrin and Phthalocyanine Antiscrapie Compounds; <i>Science</i> 287:1503-1506.																																																	
					45.					Richardson, A. et al.; The ins and outs of a molecular chaperone machine; <i>TIBS</i> 23:138-143 (1998).																																																	
					46.					Sabaté, O. et al.; Adenovirus for Neurodegenerative Diseases: In Vivo Strategies and Ex Vivo Gene Therapy Using Human Neural Progenitors; <i>Clin. Neurosci.</i> 3:317-321 (1996).																																																	
					47.					Sato, T. et al.; Transgenic mice harboring a full-length human DRPLA gene with highly expanded CAG repeats exhibit severe disease phenotype (abstract).																																																	
EXAMINER															DATE CONSIDERED																																												
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.																																																											



RECEIVED

SEP 19 2002

Sheet 4 of 4

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket No. (Optional)
P01492US1Application Number
21,916Applicant:
Zoghbi, et al.Filing Date:
05/28/99Group Art Unit
1633

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENT(S)

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

48.	Smith, David, F.; Sequence Motifs Shared between Chaperone Components Participating in the Assembly of Progesterone Receptor Complexes; <i>Biol. Chem.</i> 379:283-288 (1998).
49.	Supattapone; S. et al.; Elimination of priors by branched polyamines and implications for therapeutics; <i>Proc. Natl. Acad. Sci. USA</i> 96:14529-14534 (1999).
50.	Tagliavini, F. et al.; Effectiveness of Anthracycline Against Experimental Prion Disease in Syrian Hamsters; <i>Science</i> 276:1119-1122 (1997).
51.	Tran, Phuong B. and Miller, Richard J.; Aggregates in neurodegenerative disease: crowds and power?; <i>Trends Neurosci.</i> 22(5):194-197 (1999).
52.	Wagey, Ravenska T. E. and Krieger, Charles; Abnormalities of protein kinases in neurodegenerative diseases; <i>Prog. in Drug Res.</i> 51:135-183 (1998).
53.	Warrick, J. M. et al.; Expanded Polyglutamine Protein Forms Nuclear Inclusions and Causes Neural Degeneration in <i>Drosophila</i> ; <i>Cell</i> ; 93:939-949 (1998).
54.	Wyttenbach, A. et al.; Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease; <i>Proc. Natl. Acad. Sci. USA</i> 97:2898-2903 (2000).
55.	Xu, W. et al.; Regulation of Microphthalmia-Associated Transcription Factor MITF Protein Levels by Association with the Ubiquitin-Conjugating Enzyme hUBC9; <i>Exp. Cell. Res.</i> 255:135-143 (2000).
56.	Yamamoto, A. et al.; Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease; <i>Cell</i> ; 101:57-66 (2000).
57.	Yenari, M. A. et al.; Gene Therapy with HSP72 Is Neuroprotective in Rat Models of Stroke and Epilepsy; <i>Ann. Neurol.</i> 44:584-591 (1998).
58.	Zlokovic, Berislav V. and Apuzzo, Michael L. J.; Cellular and Molecular Neurosurgery: Pathways from Concept to Reality-Part I: Target Disorders and Concept Approaches to Gene Therapy of the Central Nervous System; <i>Neurosurgery</i> 40:789-803 (1997).
59.	Zoghbi, Huda Y. and Orr, Harry T.; Polyglutamine diseases: protein cleavage and aggregation; <i>Curr. Opin. In Neurobiol.</i> 9:566-570 (1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



Sheet 2 of 2

- TANG, Y., et al, "A Role for HDJ-2/HSDJ in Correcting Subnuclear Trafficking, Transactivation, and Transrepression Defects of a Glucocorticoid Receptor Zinc Finger Mutant" MOLECULAR BIOLOGY OF THE CELL, Vol. 8, May 1997, pp 795-809
- LU, Z., et al, "The conserved Carboxyl Terminus and Zinc Finger-like Domain of the Co-chaperone Ydj1 Assist Hsp70 in Protein Folding" THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 278, No. 10, March 6, 1998, pp 5970-5978
- BUKAU, B., et al, "The Hsp70 and Hsp60 Chaperone Machines" CELL, Vol. 92, pp 351-366, February 6, 1998
- GLOVER, J.R., et al, "Hsp104, Hsp70, and Hsp40: A Novel Chaperone System that Rescues Previously Aggregated Proteins" CELL, Vol. 94, pp 73-82, July 10, 1998
- BUSH, K.T., et al, "Proteasome Inhibition Leads to a Heat-shock Response, Induction of Endoplasmic Reticulum Chaperones, and Thermotolerance" THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 272, No. 14, April 4, 1997, pp 9086-9092
- HENRY L. PAULSON, "Human Genetics '99: Trinuletide Repeats Protein Fate in Neurodegenerative Proteinopathies: Polyglutamine Diseases John the (Mis)Fold" AM. J. HUM. GENET., 1999, 64:339-345
- ALVES-RODRIGUES, A., et al, "Ubiquitin, cellular inclusions and their roll in neurodegeneration" TRENDS NEUROSCI (1998) 21, 516-520
- BURRIGHT, E.N., et al, "SCA1 Transgenic Mice: A Model for Neurodegeneration Caused by an Expanded CAG Trinucleotide Repeat" CELL, Vol. 82, pp 937-948, September 22, 1995
- AARON CIECHANOVER, "The ubiquitin-proteasome pathway: on protein death and cell life" THE EMBO JOURNAL, Vol. 17, No. 24, pp 7151-7160, 1998
- PAULSON, H.L., et al, "Intranuclear Inclusions of Expanded Polyglutamine Protein in Spinocerebellar Ataxia Type 3" NEURON, Vol. 19, pp 333-344, August, 1997
- SKINNER, P.J., et al, "Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures" LETTERS TO NATURE, #21, #1834 pp 971-974
- STENOIEN, D.L., et al, "Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone" HUMAN MOLECULAR GENETICS, 1999, Vol. 8, No. 5, pp 731-741
- DiFIGLIA, M., et al, "Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain" SCIENCE, Vol. 277, 26 September 1997, pp 1990-1993
- CHERNOFF, Y.O., et al, "Role of the Chaperone Protein Hsp104 in Propagation of the Yeast Prion-Like Factor [psi⁺]" SCIENCE, Vol. 268, 12 May 1995, pp 880-883
- MARBER, M.S., et al, "Overexpression of the Rat Inducible 70-kD Heat Stress Protein in a Transgenic Mouse Increases the Resistance of the Heart to Ischemic Injury" J. CLIN. INVEST., Vol. 95, April 1995, pp 1446-1456
- SATO, K., et al, "HSP70 is essential to the neuroprotective effect of heat-shock" BRAIN RESEARCH 740 (1996) 117-123
- CHEETHAM, M.E., et al, "Human homologues of the bacterial heat-shock protein DnaJ are preferentially expressed in neurons" BIOCHEM. J., (1992) 284, 469-476
- DeBURMAN, S.K., et al, "Chaperone-supervised conversion of prion protein to its protease-resistant form" PROC. NATL. ACAD. SCI. USA, Vol. 94, pp 13938-13943, December 1997
- ZHOU, M., et al, "Evidence That a Rapidly Turning Over Protein, Normally Degraded by Proteasomes, Regulates hsp72 Gene Transcription in HepG2 Cells" THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 271, No. 40, October 4, 1996, pp 24769-24775
- WARRICK, J., et al, "Suppression of polyglutamine-mediated neurodegeneration in *Drosophila* by the molecular chaperone HSP70" Nature Genetics 2, Vol. 23 (1999)
- Bruening, W., et al, "Up-Regulation of Protein Chaperones Preserves Viability of Cells Expressing Toxic Cu/Zn-Superoxide Dismutase Mutants Associated with Amyotrophic Lateral Sclerosis", J. Neurochem. Vol. 72, No. 2, 1999
- Chai, Y., et al, "Analysis of the Role of Heat Shock Protein (HSP) Molecular Chaperones in Polyglutamine Disease", J. Neurosci. 19(23):10338-10347 (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

RECEIVED

SEP 19 2002

TECH CENTER 1600/2900